Düsseldorf/Paris January 30, 2020. The most important trend fore-cast by pharmaceutical experts is the continuing, worldwide increasing demand for biological drugs and biosimilars. With the recently founded, Gx Biological Solutions organization, Gerresheimer installed a dedicated team to serve the highly specific demands in the Biological playfield.
The global biopharmaceuticals market is driven by various factors, such as the increase in elderly population, surge in prevalence of chronic diseases like cancer and diabetes and growth in the adoption of biopharmaceuticals globally. Furthermore, a rise in strategic collaborations among biopharmaceuticals companies is also anticipated to supplement the growth of the biopharmaceuticals industry.
Biological drugs are specifically being used to treat e.g. rheumatism, diabetes or cancer and are usually administered parenterally. They differ from conventional drugs in their molecular structure, hence special demands on the primary packaging are to be taken care of. Gerresheimer has developed a complete package of services and products for these biological drugs and biosimilars. This includes a dedicated innovative product portfolio consisting of specialty syringes and vials, safety devices, etc. that meet the specific requirements of this continuously growing market segment. At the same time, Gerresheimer also offers a wide range of services, especially for small and medium-sized biotech companies. Whether it is advice on the right primary packaging to be used in the appropriate clinical phase or support with approval and regulatory processes, lab services and much more.
